FDA Approval Alert: The Need-to-Know | Nivolumab/Ipilimumab in Adult/Pediatric MSI-H or dMMR CRC

In April 2025, the FDA approved nivolumab in combination with ipilimumab for adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).

FDA Approves Nivolumab/Ipilimumab in Adult/Pediatric MSI-H or dMMR CRC
FDA Approves Nivolumab/Ipilimumab in Adult/Pediatric MSI-H or dMMR CRC
Article
Apr 8, 2025 5:30 PM
The FDA approved nivolumab with ipilimumab in adult and pediatric patients with CRC based on data from the phase 3 CHECKMATE-8HW trial.